← Back to Screener
Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL)
Price$4.64
Favorite Metrics
Price vs S&P 500 (26W)167.44%
Price vs S&P 500 (4W)67.61%
Market Capitalization$301.33M
All Metrics
Book Value / Share (Quarterly)$3.13
P/TBV (Annual)10.47x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.81
Price vs S&P 500 (YTD)239.57%
EPS (TTM)$-1.91
10-Day Avg Trading Volume7.95M
EPS Excl Extra (TTM)$-1.91
EPS (Annual)$-1.91
ROI (Annual)-63.39%
Cash / Share (Quarterly)$3.56
ROA (Last FY)-47.43%
EBITD / Share (TTM)$-2.12
ROE (5Y Avg)-55.52%
Cash Flow / Share (Annual)$-1.81
P/B Ratio1.39x
P/B Ratio (Quarterly)0.45x
Net Income / Employee (Annual)$-1
ROA (TTM)-40.55%
EPS Incl Extra (Annual)$-1.91
Current Ratio (Annual)6.93x
Quick Ratio (Quarterly)6.73x
3-Month Avg Trading Volume1.93M
52-Week Price Return268.25%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$8.00
P/S Ratio (Annual)4.47x
Asset Turnover (Annual)0.16x
52-Week High$6.95
EPS Excl Extra (Annual)$-1.91
CapEx CAGR (5Y)-8.79%
26-Week Price Return176.19%
Quick Ratio (Annual)6.73x
13-Week Price Return32.19%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.93x
Enterprise Value$265.337
Book Value / Share Growth (5Y)-16.10%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-245.74%
Cash / Share (Annual)$3.56
3-Month Return Std Dev191.14%
Net Income / Employee (TTM)$-1
ROE (Last FY)-63.39%
EPS Basic Excl Extra (Annual)$-1.91
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.91
Receivables Turnover (Annual)0.00x
ROI (TTM)-52.77%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$8.00
Price vs S&P 500 (52W)233.16%
Year-to-Date Return243.70%
5-Day Price Return-16.55%
EPS Normalized (Annual)$-1.91
ROA (5Y Avg)-43.55%
Net Profit Margin (Annual)-245.96%
Month-to-Date Return98.29%
Cash Flow / Share (TTM)$-3.33
EBITD / Share (Annual)$-2.12
Operating Margin (Annual)-283.57%
ROI (5Y Avg)-55.52%
EPS Basic Excl Extra (TTM)$-1.91
P/TBV (Quarterly)10.47x
P/B Ratio (Annual)0.45x
Book Value / Share (Annual)$3.13
Price vs S&P 500 (13W)29.33%
Beta2.17x
Revenue / Share (TTM)$0.00
ROE (TTM)-52.77%
52-Week Low$1.13
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.87
3.87
3.87
3.87
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ZNTLZentalis Pharmaceuticals, Inc. Common Stock | — | — | — | — | $4.64 |
LLYEli Lilly & Co. | 13.44x | 44.70% | 83.04% | 27.59% | $927.03 |
JNJJohnson & Johnson | 5.85x | 7.87% | 67.95% | 14.90% | $234.18 |
ABBVABBVIE INC. | 6.03x | 8.57% | 71.62% | -2.88% | $208.38 |
MRKMerck & Co., Inc. | 4.53x | 1.31% | 78.55% | 21.23% | $119.07 |
AZNAstraZeneca PLC | 5.30x | 8.63% | 81.31% | 21.88% | $204.80 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $151.97 |
NVONovo-Nordisk A/S | 3.70x | 6.43% | 80.98% | 20.66% | $40.52 |
ABTAbbott Laboratories | 3.74x | 6.59% | 56.50% | 8.20% | $96.81 |
PFEPfizer Inc. | 2.51x | -1.64% | 75.81% | -3.51% | $27.56 |
BMYBristol-Myers Squibb Co. | 2.55x | -0.22% | 72.63% | — | $60.17 |
About
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company developing azenosertib, a potentially first-in-class WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer. The company's lead program targets a specific patient population with limited existing treatment options and represents a focused therapeutic approach to an underserved indication.